Mr. Shaun Flanagan:

Again, that would be my expectation in light of Epidiolex getting a market authorisation on the epilepsy side. Professor Lynch might be better placed to answer this but, from my perspective, my understanding is that Epidiolex is reimbursed and that clinicians are most likely to move towards that, given it would be a licensed medicine and clinical trials would have taken place around that. I should stop and let Professor Lynch speak as that would be more appropriate.